Noninvasive disease monitoring and risk stratification by circulating tumor DNA (ctDNA)
profiling has become a potential novel strategy for patient management in B-cell lymphoma …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19
chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of …

The scarcity of malignant Hodgkin and Reed–Sternberg cells hampers tissue-based
comprehensive genomic profiling of classic Hodgkin lymphoma (cHL). By contrast, liquid …

PURPOSE Clinical outcomes of patients with CNS lymphomas (CNSLs) are remarkably
heterogeneous, yet identification of patients at high risk for treatment failure is challenging …

Inadequate molecular and clinical stratification of the patients with high-risk diffuse large B-
cell lymphoma (DLBCL) is a clinical challenge hampering the establishment of personalized …

Detection and characterization of circulating tumor DNA (ctDNA) in body fluids has the
potential to revolutionize management of patients with lymphoma. Minimal access to …

Concurrent administration of pembrolizumab with chemotherapy in untreated classic
Hodgkin lymphoma (CHL) has not been studied previously. To investigate this combination …

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy
worldwide, comprising approximately 30% of all lymphomas. Currently, 50% to 60% of …

State-of-the-art response assessment of central nervous system lymphoma (CNSL) by
magnetic resonance imaging is challenging and an insufficient predictor of treatment …